悪性固形腫瘍患者における単剤療法としての JCXH-211 を評価するための研究
悪性固形腫瘍患者におけるJCXH-211腫瘍内注射の安全性、忍容性、有効性を評価する第1相非盲検試験
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors
調査の概要
詳細な説明
The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase 1a and Phase 1b. Phase 1a has 3 stages, Single administration stage, Multiple administration stage and Visceral stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77230-1407
- University of Texas M. D. Anderson Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
All of the following conditions should be met at screening:
- Male or female patients 18-75
- Patients with malignant solid tumors that have been diagnosed by pathology and/or cytology
- Patients who have progressed on or who cannot tolerate available therapies or for whom curative therapy does not exist
- Patients with at least one non-injected measurable tumor lesion per RECIST v1.1
- Patients with lesions suitable for intratumoral injection (the lesion length is at least 10 mm and not exceeding 80 mm)
- Patients enrolled in the single and multiple administration stages of Phase 1a must agree to provide pre- and post-treatment tumor biopsy tissues
- Patients must have adequate organ and marrow functions
- Patients with treated brain metastases are eligible if meeting protocol's requirement
- Patients must be ≥ 4 weeks beyond treatment with any chemotherapy (6 weeks for nitrosoureas or mitomycin C), hormonal, biological, targeted agents, other investigational therapy or radiotherapy
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from study entry:
- Patients who have received prior IL-12 either alone or as part of a treatment regimen
- Patients who have received prior therapy with an immuno-oncology agent and were discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE)
- Patients requiring therapeutic doses of anticoagulation
- Patients with tumors that impinge on major airways, blood vessels, or nerve bundles
- Patients with a history of autoimmune disease that has the possibility of recurrence or active autoimmune disease that requires immunosuppressive medications
- Patients who had a major surgical procedure within 4 weeks prior to the first dose of study treatment
- Current or prior use of immunosuppressive medication within 2 weeks prior to the first dose of study treatment
- Patient with history of solid organ or allogenic bone marrow transplantation
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Phase 1a:Dose escalation
JCXH-211 will be delivered by intratumoral injection in 3 stages: Single administration stage A single administration of JCXH-211 administered to cutaneous or subcutaneous lesions in escalating doses. Multiple administration stage Up to 3 doses of JCXH-211 administered to a cutaneous or subcutaneous lesion in escalating doses. Assigned dose to be determined on the data from the single administration arm. Visceral administration stage JCXH-211 administered to a visceral lesion in escalating doses. Assigned dose to be determined on the data from the single and multiple administration arms. |
JCXH-211 administered once every 28 days |
|
実験的:Phase 1b:Dose expansion
JCXH-211 will be delivered by intratumoral injection. The dose to be used will be determined after review of the data from Phase 1a. |
JCXH-211 administered once every 28 days |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dose limiting toxicity
時間枠:Day 1 to Day 29
|
Dose limiting toxicity, evaluated in the single administration stage of Phase 1a, which will be used to determine the MTD and to determine dose escalation |
Day 1 to Day 29
|
|
Incidence of adverse events (Safety and Tolerability)
時間枠:From consent to 30 days after the last dose of study drug
|
Safety and tolerability as determined by the incidence of adverse events (AEs), including severe AEs and serious AEs (SAEs) |
From consent to 30 days after the last dose of study drug
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective response rate (ORR)
時間枠:Up to 12 months
|
Objective response rate is defined as the proportion of patients that achieve a complete response (CR) or partial response (PR) during the study participation. |
Up to 12 months
|
|
Duration of response (DOR)
時間枠:Up to 12 months following first reported response
|
Duration of response is defined as the time from the first assessment of tumor as CR or PR to the first assessment as progressive disease or death from any cause. |
Up to 12 months following first reported response
|
|
Time to response (TTR)
時間枠:Up to 12 months from the start of study therapy
|
Time to response is defined as the time from Day 1 until the first documentation of objective response (CR or PR). |
Up to 12 months from the start of study therapy
|
|
Disease control rate (DCR)
時間枠:Up to 12 months
|
Disease control rate is defined as the proportion of patients with CR or PR or stable disease (SD) with the DOR ≥ 12 weeks observed from Day 1 to disease progression. |
Up to 12 months
|
|
Progression-free survival (PFS)
時間枠:Up to 12 months
|
Progression-free survival is defined as the time from Day 1 to disease progression or death from any cause, whichever occurs earlier. |
Up to 12 months
|
|
Overall survival (OS)
時間枠:Up to 24 months
|
Overall survival is defined as the time from Day 1 until death due to any cause. |
Up to 24 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。